The library will operate on a duty schedule between 22 December 2025 and 4 January 2026. During this period, it will be possible to upload publications, but all other services will be suspended.
Q1
Biochemistry, Genetics and Molecular Biology (miscellaneous)
2022
2.
Bakos, I.,
Mahdi, M.,
Kardos, L.,
Nagy, A.,
Várkonyi, I.:
Clinical Spectrum and CSF Findings in Patients with West-Nile Virus Infection, a Retrospective Cohort Review.
Diagnostics. 12 (4), 1-9, (article identifier: 805), 2022.
Merkely, B.,
Szabó, A.,
Kosztin, A.,
Berényi, E.,
Sebestyén, A.,
Lengyel, C.,
Merkely, G.,
Karády, J.,
Várkonyi, I.,
Papp, C.,
Miseta, A.,
Betlehem, J.,
Burián, K.,
Csóka, I.,
Vásárhelyi, B.,
Ludwig, E.,
Prinz, G.,
Sinkó, J.,
Hankó, B.,
Varga, P.,
Fülöp, G. Á.,
Mag, K.,
Vokó, Z.,
HUNgarian COronaVirus-19 Epidemiological Research (H-UNCOVER) investigators:
Novel coronavirus epidemic in the Hungarian population, a cross-sectional nationwide survey to support the exit policy in Hungary.
GeroScience. 42 (4), 1063-1074, 2020.
Misák, O.,
Várkonyi, I.,
Kenéz, É.,
Rákóczi, É.:
Findings of hospital a surveillance-based outcome evaluation study for Clostridium difficile associated colitis.
Final programme 2017, 214, 2017.
Foster, G. R.,
Coppola, C.,
Derbala, M.,
Ferenci, P.,
Orlandini, A.,
Reddy, K. R.,
Tallarico, L.,
Shiffman, M. L.,
Ahlers, S.,
Bakalos, G.,
Hassanein, T.,
GUARD-C Study Group:
Impact of Safety-Related Dose Reductions or Discontinuations on Sustained Virologic Response in HCV-Infected Patients: results from the GUARD-C Cohort.
PLoS One. 11 (3), e0151703, (article identifier: 0151703), 2016.
Kirsner, R. S.,
Vanscheidt, W.,
Keast, D. H.,
Lantis, J. C.,
Dove, C. R.,
Cazzell, S. M.,
Vartivarian, M.,
Augustin, M.,
Marston, W. A.,
McCoy, N. D.,
Cargill, D. I.,
Lee, T. D.,
Dickerson, J. E.,
Slade, H. B.,
HP802-247 Study Group:
Phase 3 evaluation of HP802-247 in the treatment of chronic venous leg ulcers.
Wound Repair Regen. 24 (5), 894-903, 2016.
Novák, Z.,
Yanez, A.,
Kiss, I.,
Kuna, P.,
Tortajada-Girbes, M.,
Valiente, R.,
Bilastine Paediatric Safety Study Group:
Safety and tolerability of bilastine 10 mg administered for 12 weeks in children with allergic diseases.
Pediatr. Allergy Immunol. 27 (5), 493-498, 2016.
Várkonyi, I.,
Chappey, C.,
Giraudon, M.,
Burleigh, L.:
A part-randomized study of intravenous oseltamivir in adolescents and adults.
Eur. J. Clin. Microbiol. Infect. Dis. 34 (6), 1181-1188, 2015.
de Bruijne, J.,
van Vliet, A.,
Weegink, C. J.,
Mazur, W.,
Wiercinska-Drapalo, A.,
Simon, K.,
Cholewinska-Szymanska, G.,
Kapocsi, J.,
Várkonyi, I.,
Zhou, X. J.,
Temam, M. F.,
Molles, J.,
Chen, J.,
Pietropaolo, K.,
McCarville, J. F.,
Sullivan-Bolyai, J. Z.,
Mayers, D.,
Reesink, H.:
Rapid decline of viral RNA in chronic hepatitis C patients treated once daily with IDX320: a novel macrocyclic HCV protease inhibitor.
Antivir. Ther. 17 (4), 633-642, 2012.
Várkonyi, I.,
Makai, I.,
Papdiné Nyíri, G.,
Bacskó, G.,
Kardos, L.:
A császármetszés posztoperatív sebfertőzés surveillance tapasztalatai a debreceni Kenézy Kórházban.
Orvosi Hetilap. 152 (1), 14-22, 2011.
Guyader, D.,
Bogomolov, P.,
Kobalava, Z.,
Moiseev, V.,
Szlávik, J.,
Astruc, B.,
Várkonyi, I.,
Sullivan, T.,
Horgan, K.,
Bexon, A.,
Arbeit, R.:
Imo-2125 plus ribavirin gives substantial first-dose viral load reductions, cumulative anti-viral effect, is well tolerated in naive genotype1 hcv patients: a phase 1 trial.
J. Hepatol. 54, S478-, 2011.
